Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

China National Biotec Is Said to Plan $1.5 Billion Hong Kong IPO

Don't Miss Out —
Follow us on:

Jan. 14 (Bloomberg) -- China National Biotec Group, China’s largest biotechnology company, is planning an initial public offering to raise about $1.5 billion in Hong Kong, said two people with knowledge of the matter.

The unit of Sinopharm Group Co. may file an application to Hong Kong’s stock exchange by the end of March and start the offering as early as in the second quarter, said the people, who asked not to be identified because the information is private. Sinopharm is China’s biggest pharmaceutical distributor by market value.

China International Capital Corp., Morgan Stanley and UBS AG will manage the offering, the people said. An external spokeswoman for National Biotec declined to comment on the plan.

National Biotec, based in Beijing, is the fourth-biggest vaccine maker in the world, according to its website. It has about 8.6 billion yuan ($1.4 billion) of assets and annual sales of more than 5 billion yuan, the website shows.

To contact the reporter on this story: Fox Hu in Hong Kong at

To contact the editor responsible for this story: Philip Lagerkranser at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.